Last reviewed · How we verify

rTG — Competitive Intelligence Brief

rTG (rTG) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme (tissue transglutaminase). Area: Wound Care / Hemostasis / Surgery.

marketed Enzyme (tissue transglutaminase) Tissue transglutaminase (TG2/TGM2) Wound Care / Hemostasis / Surgery Small molecule Live · refreshed every 30 min

Target snapshot

rTG (rTG) — Gottfried Wilhelm Leibniz Universität Hannover. rTG is a recombinant human tissue transglutaminase used as a therapeutic enzyme to cross-link and stabilize proteins in wound healing and tissue repair applications.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
rTG TARGET rTG Gottfried Wilhelm Leibniz Universität Hannover marketed Enzyme (tissue transglutaminase) Tissue transglutaminase (TG2/TGM2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme (tissue transglutaminase) class)

  1. Gottfried Wilhelm Leibniz Universität Hannover · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rTG — Competitive Intelligence Brief. https://druglandscape.com/ci/rtg. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: